Study summary
A TROP2 antibody-drug conjugate beat chemotherapy after EGFR pills stopped working
8.3months without progression, vs 4.3 with chemotherapy
What was tested
Sacituzumab tirumotecan (sac-TMT), an antibody that delivers chemotherapy into cancer cells carrying TROP2, against pemetrexed and platinum chemotherapy after EGFR pills stopped working. Run in China.
What they found
- Median progression-free survival was 8.3 vs 4.3 months.
- Overall survival was longer (18-month survival 65.8% vs 48.0%).
- Low white blood cell counts were the most common severe side effect.
What it means
Global trials (run by Merck) are testing whether the result holds outside China.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.